Donidalorsen · Dawnzera
RNA / oligonucleotide
Evidence outlook
Approved: Hereditary Angioedema
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Hereditary angioedema (Dawnzera, donidalorsen); marketing authorisation holder Otsuka Pharmaceutical
- Patients 12 years and older with hereditary angioedema (HAE), to prevent angioedema attacks
- Routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04030598 NCT04030598 · Hereditary Angioedema In the randomized, double-blind, placebo-controlled portion of this small Phase 2 trial, donidalorsen reduced the monthly hereditary angioedema attack rate by about 90% compared with placebo (p=0.001). The comparison was randomized and blinded, but only 20 patients were included (14 on donidalorsen, 6 on placebo), a small sample for a definitive readout. Registry: NCT04030598 | 2 | Time-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 17 2021-01-04 | Time-normalized Number of HAE Attacks (Per Month) From Week 1 to Week 17 (Week 1 to Week 17): Part A: Placebo 2.21 HAE attacks per month (Standard Deviation 1.558) | Part A: Donidalorsen 80 mg 0.23 HAE attacks per month (Standard Deviation 0.268) | Part B: Donidalorsen 80 mg 1.52 HAE attacks per month (Standard Deviation 2.221) | Partial signal | link ↗ |
View 1 more trial
HAE NCT05139810 · Hereditary Angioedema This randomized, quadruple-blind, placebo-controlled Phase 3 trial in 91 patients with hereditary angioedema tested donidalorsen given every 4 weeks or every 8 weeks against placebo. Both dosing regimens significantly reduced the monthly attack rate compared with placebo (81% and 55% reductions respectively, both p<=0.004). Registry: NCT05139810 | 3 | Time-Normalized Investigator-Confirmed (IC) HAE Attack Rate (Per Month) From Week 1 to Week 25 2023-11-09 | Time-Normalized Investigator-Confirmed (IC) HAE Attack Rate (Per Month) From Week 1 to Week 25 (Week 1 to Week 25): Pooled Placebo 2.26 HAE attacks per month (95% CI 1.657 to 3.085) | Cohort A: Donidalorsen 80 mg 0.44 HAE attacks per month (95% CI 0.265 to 0.727) | Cohort B: Donidalorsen 80 mg 1.02 HAE attacks per month (95% CI 0.651 to 1.594) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dawnzera (Donidalorsen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.